COVID-19 Treatment Guidelines

Introduction to Ivermectin

The Infectious Diseases Society of America (IDSA) recommends against ivermectin for hospitalized patients with COVID-19 (Conditional recommendation, Very low certainty of evidence) and for ambulatory persons with COVID-19 (Strong recommendation, Moderate certainty of evidence) 1
Multiple randomized controlled trials have shown no proven effect on mortality in hospitalized patients with COVID-19 (RR: 0.54; 95% CI: 0.28, 1.03) and in ambulatory patients with COVID-19 (RR: 0.83; 95% CI: 0.50, 1.37) 2

Ivermectin has no beneficial effect on the need for mechanical ventilation, hospitalization rates, or viral clearance at day seven in patients with COVID-19 2
The concentrations required to inhibit SARS-CoV-2 in vitro are considerably higher than those achievable in human plasma and lung tissue 2

Multiple well-designed RCTs have consistently failed to show meaningful clinical benefit of ivermectin for COVID-19 treatment or prevention 2, 1
The Front Line Doctors Ivermectin Protocol contradicts current evidence-based medicine, and healthcare providers should follow established guidelines from major medical societies that recommend against using ivermectin for COVID-19 treatment or prevention 2, 1
Ivermectin is FDA-approved only for the treatment of strongyloidiasis and onchocerciasis (river blindness), with no proven efficacy for COVID-19 or other viral infections despite its in vitro activity 2

The FDA recommends a single oral dose of 200 mcg/kg for intestinal strongyloidiasis, with efficacy measured by absence of larvae in follow-up stool examinations 2
The FDA recommends a single oral dose of 150 mcg/kg given annually for onchocerciasis (river blindness), causing a dramatic reduction in skin microfilariae counts 2
Ivermectin is effective against microfilariae of Wuchereria bancrofti and Brugia malayi, used in mass treatment programs for lymphatic filariasis, although not officially FDA-approved for this indication 2
Ivermectin is particularly effective for crusted (Norwegian) scabies and head lice, with strong clinical evidence supporting its use 2

Ivermectin binds selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, increasing cell membrane permeability to chloride ions, resulting in hyperpolarization, paralysis, and death of parasites 2
Ivermectin is metabolized in the liver primarily by CYP3A4, with a plasma half-life of approximately 18 hours following oral administration, and is excreted almost exclusively in feces over approximately 12 days 2

Common adverse effects of ivermectin include edema, rash, headache, and ocular complaints, with a risk of severe systemic postural hypotension, and severe encephalopathy when treating patients with high microfilarial loads 2, 1
Ivermectin can cause adverse effects such as edema, rash, headache, and ocular complaints, and may interact with P-glycoprotein inhibitors to increase neurotoxicity 1, 2
The mechanism of toxicity of ivermectin involves binding to glutamate, GABA, and glycine receptors, highlighting the need for caution when prescribing off-label 1, 2

The use of ivermectin for off-label indications, except for specific parasitic conditions, is not supported due to insufficient evidence, including its use for COVID-19 or cancer treatment 1, 2
The use of ivermectin for cancer treatment is not recommended due to insufficient clinical evidence, with research remaining primarily preclinical 1, 2, 3
Healthcare providers should guide patients toward established cancer therapies with proven benefits for mortality, morbidity, and quality of life outcomes, and encourage patient participation in properly designed clinical trials if interested in investigational approaches 3
Off-label prescribing of ivermectin during public health emergencies raises ethical concerns about evidence standards, and healthcare providers should verify evidence exists for the specific off-label indication and ensure appropriate dosing based on condition and patient factors 1, 2